Michael Goodman, M.D., F.A.C.P., Curriculum Vitae - Glacier Oncology

Recommendations

Info

Staff Liaison, Division of Animal Resources, Scripps Clinic and Research Foundation, La Jolla,California, April 1986-1992Committees (continued)Member, Animal Research Committee, Scripps Clinic and Research Foundation, 1986-1992Member, Nonhuman Primate Research Committee, Scripps Clinic and Research Fdn 1986-92Reviewer, Advisory Committee, Medical Biochemistry Study Section, National Institutes ofHealth, 1987,1988Reviewer, National Science Foundation, 1982Reviewer, Arthritis Society of Canada, 1985-1996Advisor, World Health Organization, Geneva, Switzerland, 1990Member, Clinical Protocol Committee, Scripps Clinic and Research Foundation, 1992-1996National Cancer Institute Site Visit Committee Member, Advisory Committee, National Institutesof Health, 1994-1996.Member, Clinical Protocol Committee, Kalispell Regional Medical Center, Kalispell, MT, 1997-presentMember, Radiation Oncology Review Commitee, Kalispell Regional Med Center, Kalispell, MTChief, Section of Oncology, Kalispell Regional Medical Center, Kalispell, MT, 1997-1999Member, Kalispell Regional Medical Center General Tumor Board, 2010 -presentMember, Kalispell Regional Medical Center Breast Tumor Board, 2010 - presentClinical Trials Designed1. A Phase I study of the safety, pharmacokinetics and immunologic effects of loxoribine (7-allyl-8-oxoguanosine) in patients with advanced malignancies who have failed standard therapy. B.Meisenberg, D.L. McKee, M.G. Goodman. Scripps Clinic and Research Fdn.2. Loxoribine—a phase I/II study of the safety, pharmacokinetics, and immunologic effects inpatients with advanced, previously treated chronic lymphocytic leukemia. M.P Kosty, L.D.Piro, and M.G. Goodman. Scripps Clinic and Research Foundation.
3. Immunophenotypic and Functional assessment of the lymphohematopoietic system before andafter high-dose chemotherapy and autologous stem cell support. B. Meisenberg, M.G.Goodman, D.L. McKee. Scripps Clinic and Research Foundation.Clinical Trials Designed (continued)4. A Phase I/II study of the pharmacokinetics and immunologic efficacy of loxoribine (7- allyl-8-oxoguanosine) in patients with metastatic melanoma who have failed standard therapy. B.Meisenberg, M.G. Goodman, D.L. McKee. Scripps Clinic and Research Fdn.5. A dose-escalation study of the immunologic efficacy of loxoribine (7-allyl-8-oxoguanosine) inpatients with common variable immunodeficiency disease. M. G. Goodman, R. Simon.Scripps Clinic and Research Foundation.Industrial Consultant ActivityOrtho Pharmaceutical Corp. of Johnson and Johnson, New Brunswick, N. J. 1981-1992.Cytotec, Inc., San Diego, California 1984-86.La Jolla Pharmaceuticals, La Jolla, California 1991.Metra Biosystems, Palo Alto, California 1992.Sandoz Pharmaceuticals, Ltd, Basel Switzerland. 1995.Preceptorship Lecture Series, Green Cancer Center, Scripps ClinicAmgen Corporation, Thousand Oaks, California, 1993-1996.Immunex Corporation, Seattle, Washington, 1993-1996.Community ActivitiesMember, Yale Alumni Schools Committee, 1986-1994Member, La Jolla-UCSD Symphony and Chorus. 1977-1978, 1989-1996Member, Glacier Chorale. 1996-1999
Page 1 and 2: CURRICULUM VITAEMichael Gordon Good
Page 3: Diplomate, American Board of Intern
Page 7 and 8: (continued)11. Goodman, M.G., and W
Page 9 and 10: 12. Goodman, M.G. and W.O. Weigle.
Page 11 and 12: esistance to metabolic processing b
Page 13 and 14: L.F. Thompson and R.W.E. Watts, eds
Page 15 and 16: 83. Goodman, M. G., S. Wormsley, J.
Page 17 and 18: 11. Goodman, M.G. and W.O. Weigle.
Page 19 and 20: McKee, D, Earth, N, Guthiel, J. Com
Page 21: new and developing treatments for C

Michael Goodman, M.D., F.A.C.P., Curriculum Vitae - Glacier Oncology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?